SBC Medical Group Holdings Inc. (SBC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
SBC Medical Group Re-Accelerates Growth as EBITDA Surges 32% in Q2
SBC Medical Group NASDAQ: SBC said its growth re-accelerated in the second quarter of 2026 following structural reforms undertaken in 2025, with profit growth exceeding revenue growth as the company expanded management services revenue and increased service fees.
SBC Medical Group Q2 Growth Re-Accelerates as EBITDA Surges 32%
SBC Medical Group NASDAQ: SBC said its growth re-accelerated in the second quarter of 2026 as the company completed structural reforms undertaken in 2025, expanded its clinic network and increased management-services revenue.
SBC Medical Group Holdings Incorporated (SBC) Q2 2026 Earnings Call Transcript
SBC Medical Group Holdings Incorporated (SBC) Q2 2026 Earnings Call Transcript
SBC Medical Group Q2 Earnings Call Highlights
SBC Medical Group NASDAQ: SBC said its second-quarter 2026 results reflected a reacceleration in growth following structural reforms undertaken in 2025, with adjusted EBITDA rising faster than revenue despite the effect of a weaker yen on reported results.
SBC Medical Group Shareholders Approve Board, Charter Changes at Annual Meeting
SBC Medical Group NASDAQ: SBC held its 2026 annual meeting of stockholders in a virtual format, with Chairman and Chief Executive Officer Yoshiyuki Aikawa presiding over the meeting.
SBC Medical Group Q1 Earnings Call Highlights
SBC Medical Group NASDAQ: SBC reported first-quarter 2026 revenue of $43 million, down 9% from a year earlier, as management said prior fee structure revisions continued to weigh on reported results even as underlying clinic activity improved.
SBC Medical: Scalable Profits Undermined By Governance Overhang, Still Worth A Look
SBC operates a highly profitable franchise model supporting over 250 aesthetic clinics, with 2024 operating margins exceeding 40 percent. The company generates strong returns on invested capital, with return on net operating assets reaching 116.9 percent in 2024. Revenue growth is supported by clinic expansion, rising inbound patient volume, and international acquisitions, including a recent entry into Southeast Asia.
